Skip to main content

Veracyte, Inc. (VCYT)

NASDAQ: VCYT · IEX Real-Time Price · USD
46.36 0.45 (0.98%)
Oct 26, 2021 4:00 PM EDT - Market closed
Market Cap3.21B
Revenue (ttm)157.47M
Net Income (ttm)-63.07M
Shares Out67.32M
EPS (ttm)-1.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume349,467
Open46.33
Previous Close45.91
Day's Range45.02 - 46.79
52-Week Range32.87 - 86.03
Beta0.83
AnalystsBuy
Price Target63.17 (+36.3%)
Earnings DateNov 9, 2021

About VCYT

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without ...

IndustryBiotechnology
IPO DateOct 30, 2013
CEOBonnie Anderson
Employees320
Stock ExchangeNASDAQ
Ticker SymbolVCYT
Full Company Profile

Financial Performance

In 2020, Veracyte's revenue was $117.48 million, a decrease of -2.40% compared to the previous year's $120.37 million. Losses were -$34.91 million, 177.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Veracyte stock is "Buy." The 12-month stock price forecast is 63.17, which is an increase of 36.26% from the latest price.

Price Target
$63.17
(36.26% upside)
Analyst Consensus: Buy

News

Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinical...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data presented at the ASTRO 2021 Annual Meeting validate the prognostic ability of Veracyte's Decipher Prostate genomic classifier.

1 day ago - Business Wire

New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Clas...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data to be presented at ASTRO 2021 reinforce the clinical utility of Veracyte's Decipher Prostate genomic classifier

1 week ago - Business Wire

New Publication Demonstrates Ability of Veracyte's Decipher Bladder Test to Identify Tumors Most Likely to Respond to...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data published in the Journal of Urology demonstrate Veracyte's Decipher Bladder test can identify tumors most likely to respond to chemotherapy

1 week ago - Business Wire

Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

2 weeks ago - Business Wire

New Clinical Utility Data Confirm Veracyte's Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diag...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data to be presented at CHEST show Veracyte's Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic pulmonary fibrosis.

2 weeks ago - Business Wire

Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung C...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment

2 weeks ago - Business Wire

New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte's Genomic Diagnostic Tests in Lung C...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data to be presented at CHEST 2021 will showcase performance of Veracyte's genomic diagnostic tests in lung cancer and other lung diseases

2 weeks ago - Business Wire

Is Veracyte Still a Buy After Its Recent Rally?

Shares of the genetic diagnostics company are down nearly 50% from their 52-week high in February.

3 weeks ago - The Motley Fool

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide S...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New NCCN Guidelines Recommend Use of Veracyte's Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men After Radical Prostatectomy

1 month ago - Business Wire

Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte has appointed Dr. Joshua Klopper as Medical Director, Endocrinology.

1 month ago - Business Wire

Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

1 month ago - Business Wire

Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--South San Francisco-based Veracyte was named a Bay Area Top Workplace for the eighth consecutive year.

2 months ago - Business Wire

Cathie Wood Whittles Down 2 Positions in July

Catherine Wood (Trades, Portfolio) disclosed earlier this week her firm, ARK Investment Management, reduced two of its positions in July.

Other symbols:AQB
2 months ago - GuruFocus

Veracyte Completes Acquisition of HalioDx

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced that the company has completed the acquisition of HalioDx.

2 months ago - Business Wire

Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 48.00% and 15.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Veracyte Announces Second Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Second Quarter 2021 Financial Results

2 months ago - Business Wire

After Naming a New CFO, Is This Genetic Diagnostics Company a Buy?

Veracyte appointed Rebecca Chambers, who boasts a wealth of financial executive experience, to the position.

Other symbols:ILMNOM
2 months ago - The Motley Fool

New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Published data suggest Veracyte's Decipher Prostate Biopsy genomic classifier may help guide the use of active surveillance in prostate cancer

2 months ago - Business Wire

Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Compa...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth

3 months ago - Business Wire

Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021.

3 months ago - Business Wire

Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Appointments of Rob Brainin and Bill Zondler to Executive Leadership Team, Supporting Global Expansion

3 months ago - Business Wire

Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte has appointed Dr. Bill Bulman and Dr. Kelly Marcom as the company's medical directors of Lung Cancer and Breast Cancer, respectively.

3 months ago - Business Wire

New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte's Decipher Prostate Genomic Classifier...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced that new data demonstrating the prognostic utility of the Decipher® Prostate genomic classifier were published in JAMA Oncology.

4 months ago - Business Wire

Moving Average Crossover Alert: Veracyte (VCYT)

Veracyte (VCYT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

4 months ago - Zacks Investment Research